Anavex Life Sciences Corp (AVXL)

[boi568]

The 52 week SAVA Phase 3 will be to evaluate simufilam for symptomatic effect, and the 76 week study will examine disease modifying effects. Our 2b/3 study is 48 weeks, and we will presumably find out what 2-73 does with AD without need for another study. We are, however, undertaking a post-trial OLE, while SAVA's release today does not mention an OLE after either trial.

Two other interesting points: SAVA says their 52 week symptomatic study is intended to "demonstrate improved cognition and daily function" for patients enrolled in their treatment arm. The 76 week disease modification study is intended to show "a slower rate of decline in cognition and daily function" for patients in their treated arm.

So I guess if the effect of simufilam is temporary, and then patients continue to decline -- similar to (but presumably safer and a bit more efficacious than) Aricept -- SAVA will declare victory on both fronts. I believe Missling is more ambitious.